Our proprietary decellularization process separates stromal cells and extracellular matrix (ECM) from a small omental biopsy sample a, A thermo-responsive hydrogel is produced from the ECM. The stromal cells are reprogramed into induced pluripotent stem cells (iPSCs) which are then incorporated into the hydrogel before being differentiated into the desired functional tissue using our patent-pending methodology.
Our proprietary hydrogel combined with motor neurons creates functional spinal cord implants that can bridge injured spinal cord tissue. After successful pre-clinical results, a first human clinical trial is scheduled for 2022.
In 2019, Matricelf licensed the technology that enabled printing the first [functioning] 3D human heart from cells and matrix derived from a human omentum biopsy from Tel Aviv University.
Matricelf’s novel regenerative medicine platform aims to cure a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction et al.